Lobular Neoplasia

AbstractPurpose of ReviewToday, the term lobular neoplasia (LN) incorporates atypical lobular hyperplasia (ALH), classical lobular carcinoma in situ (C-LCIS) and nonclassical lobular carcinoma in situ (NC-LCIS). These neoplastic lesions are thought of as risk indicators and non-obligate precursors of invasive breast cancer. This review highlights the current literature and up-to-date treatment recommendations for ALH, C-LCIS, and NC-LCIS.Recent FindingsCurrently, NC-LCIS requires surgical excision to rule out a concurrent carcinoma; but a core biopsy diagnosis of ALH or C-LCIS can be safely managed with close clinical and imaging observation, elevated future breast cancer risk counseling and consideration for chemoprevention. Controversy regarding categorizing NC-LCIS remains with respect to its histologic features and terminology.SummaryThe treatment and surveillance recommendations for LN continue to evolve. Overall, the treatment of LN requires a multidisciplinary approach to ensure appropriate screening and comprehensive counseling about the elevated lifetime breast cancer risk and about standard and investigational breast cancer risk-reducing options in this patient population.
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research